A comprehensive and systematic analysis of Dihydrolipoamide S-acetyltransferase (DLAT) as a novel prognostic biomarker in pan-cancer and glioma
Oncology Research · 2024
DOI: 10.32604/or.2024.048138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2024. Verfasst von Hui Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, West China Hospital, Sichuan University, Chengdu, 610041, China. Hauptthemen laut MEDLINE: Glioma, Biomarkers, Tumor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Dihydrolipoamide S-acetyltransferase (DLAT) is a subunit of the pyruvate dehydrogenase complex (PDC), a rate-limiting enzyme complex, that can participate in either glycolysis or the tricarboxylic acid cycle (TCA). However, the pathogenesis is not fully understood. We aimed to perform a more systematic and comprehensive analysis of DLAT in the occurrence and progression of tumors, and to investigate its function in patients' prognosis and immunotherapy.
Methods
The differential expression, diagnosis, prognosis, genetic and epigenetic alterations, tumor microenvironment, stemness, immune infiltration cells, function enrichment, single-cell analysis, and drug response across cancers were conducted based on multiple computational tools. Additionally, we validated its carcinogenic effect and possible mechanism in glioma cells.
Results
We exhibited that DLAT expression was increased in most tumors, especially in glioma, and affected the survival of tumor patients. DLAT was related to RNA modification genes, DNA methylation, immune infiltration, and immune infiltration cells, including CD4+ T cells, CD8+ T cells, Tregs, and cancer-associated fibroblasts. Single-cell analysis displayed that DLAT might regulate cancer by mediating angiogenesis, inflammation, and stemness. Enrichment analysis revealed that DLAT might take part in the cell cycle pathway. Increased expression of DLAT leads tumor cells to be more resistant to many kinds of compounds, including PI3Kβ inhibitors, PKC inhibitors, HSP90 inhibitors, and MEK inhibitors. In addition, glioma cells with DLAT silence inhibited proliferation, migration, and invasion ability, and promoted cell apoptosis.
Conclusion
We conducted a comprehensive analysis of DLAT in the occurrence and progression of tumors, and its possible functions and mechanisms. DLAT is a potential diagnostic, prognostic, and immunotherapeutic biomarker for cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Zitieren
APA
Zhou, H., Yu, Z., Xu, J., Wang, Z., Tao, Y., Wang, J., Yang, P., Yang, J., & Niu, T. (2024). A comprehensive and systematic analysis of Dihydrolipoamide S-acetyltransferase (DLAT) as a novel prognostic biomarker in pan-cancer and glioma. Oncology Research. https://doi.org/10.32604/or.2024.048138
Vancouver
Zhou H, Yu Z, Xu J, Wang Z, Tao Y, Wang J, et al. A comprehensive and systematic analysis of Dihydrolipoamide S-acetyltransferase (DLAT) as a novel prognostic biomarker in pan-cancer and glioma. Oncology Research. 2024. doi:10.32604/or.2024.048138
BibTeX
@article{Zhou2024,
author = {Zhou, Hui and Yu, Zhengyu and Xu, Jing and Wang, Zhongwang and Tao, Yali and Wang, Jinjin and Yang, Peipei and Yang, Jinrong and Niu, Ting},
title = {A comprehensive and systematic analysis of Dihydrolipoamide S-acetyltransferase (DLAT) as a novel prognostic biomarker in pan-cancer and glioma},
journal = {Oncology Research},
year = {2024},
doi = {10.32604/or.2024.048138}
}
EUVIMED